Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioNTech SE stock logo
BNTX
BioNTech
$88.05
-4.3%
$108.81
$76.53
$131.49
$21.13B1.07843,634 shs1.04 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$25.11
-2.4%
$33.55
$23.76
$170.47
$9.71B2.237.05 million shs16.04 million shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$9.46
-5.5%
$10.62
$9.42
$13.06
$6.75B1.255.31 million shs10.14 million shs
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$13.83
-6.9%
$16.52
$12.51
$22.80
$15.68B0.829.74 million shs18.09 million shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioNTech SE stock logo
BNTX
BioNTech
0.00%-7.27%-20.55%-23.96%-3.01%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%-19.31%-26.79%-40.47%-75.19%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
0.00%-8.86%-10.75%-19.08%-17.81%
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
0.00%-8.14%-9.74%-34.89%-2.12%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioNTech SE stock logo
BNTX
BioNTech
2.6692 of 5 stars
4.42.00.00.02.50.80.6
Moderna, Inc. stock logo
MRNA
Moderna
4.2061 of 5 stars
4.01.00.04.62.02.51.3
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
2.0917 of 5 stars
3.51.00.00.03.03.30.0
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
2.3735 of 5 stars
3.43.00.80.02.70.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioNTech SE stock logo
BNTX
BioNTech
2.89
Moderate Buy$143.4462.90% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$59.00134.97% Upside
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
3.00
Buy$17.5084.99% Upside
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
2.86
Moderate Buy$23.4369.40% Upside

Current Analyst Ratings Breakdown

Latest ROIV, MRNA, BNTX, and TEVA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/1/2025
BioNTech SE stock logo
BNTX
BioNTech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$150.00 ➝ $145.00
3/21/2025
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$40.00 ➝ $33.00
3/13/2025
BioNTech SE stock logo
BNTX
BioNTech
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$145.00
3/13/2025
Moderna, Inc. stock logo
MRNA
Moderna
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$40.00
3/11/2025
BioNTech SE stock logo
BNTX
BioNTech
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$145.00 ➝ $139.00
3/11/2025
BioNTech SE stock logo
BNTX
BioNTech
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$171.44 ➝ $171.44
3/11/2025
BioNTech SE stock logo
BNTX
BioNTech
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$130.00 ➝ $143.00
3/6/2025
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$23.00 ➝ $20.00
3/4/2025
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
2/19/2025
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$96.00 ➝ $78.00
2/18/2025
Moderna, Inc. stock logo
MRNA
Moderna
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform$40.00 ➝ $40.00
(Data available from 4/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioNTech SE stock logo
BNTX
BioNTech
$2.75B7.68$3.79 per share23.25$92.17 per share0.96
Moderna, Inc. stock logo
MRNA
Moderna
$3.20B3.03N/AN/A$28.33 per share0.89
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$122.59M55.07N/AN/A$7.76 per share1.22
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$16.54B0.95$2.74 per share5.05$4.75 per share2.91
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioNTech SE stock logo
BNTX
BioNTech
$1.01B-$3.00N/AN/AN/A-15.16%-2.35%-2.05%5/5/2025 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$9.28N/AN/AN/A-110.04%-28.74%-21.83%5/1/2025 (Estimated)
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$4.35B-$0.15N/AN/AN/A-119.54%-14.05%-12.81%5/29/2025 (Estimated)
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
-$1.64B-$1.45N/A5.261.44-9.91%42.46%6.65%5/7/2025 (Estimated)

Latest ROIV, MRNA, BNTX, and TEVA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2025N/A
Moderna, Inc. stock logo
MRNA
Moderna
-$2.90N/AN/AN/A$130.35 millionN/A
3/10/2025Q4 24
BioNTech SE stock logo
BNTX
BioNTech
$0.38$1.08+$0.70$1.15$1.24 billion$1.19 billion
2/10/2025Q3 2025
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$0.24-$0.20+$0.04$0.23$4.75 millionN/A
1/29/2025Q4 2024
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$0.69$0.70+$0.01-$0.19$4.10 billionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioNTech SE stock logo
BNTX
BioNTech
$1.531.74%N/AN/A N/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/AN/AN/AN/AN/A
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$1.017.31%N/AN/A N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioNTech SE stock logo
BNTX
BioNTech
0.01
7.33
7.21
Moderna, Inc. stock logo
MRNA
Moderna
N/A
3.67
3.62
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/A
37.91
37.91
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
2.97
0.98
0.75

Institutional Ownership

CompanyInstitutional Ownership
BioNTech SE stock logo
BNTX
BioNTech
15.52%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
64.76%
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
54.05%

Insider Ownership

CompanyInsider Ownership
BioNTech SE stock logo
BNTX
BioNTech
19.20%
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
7.90%
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
0.55%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioNTech SE stock logo
BNTX
BioNTech
3,080239.97 million193.71 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
3,900386.62 million324.40 millionOptionable
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
860713.55 million657.18 millionOptionable
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
36,8001.13 billion1.13 billionOptionable

Recent News About These Companies

Zacks Research Analysts Increase Earnings Estimates for TEVA
Teva announces presentation of survey study on TEV-‘749

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
BioNTech stock logo

BioNTech NASDAQ:BNTX

$88.05 -3.96 (-4.30%)
Closing price 04/4/2025 04:00 PM Eastern
Extended Trading
$88.06 +0.01 (+0.01%)
As of 04/4/2025 06:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Moderna stock logo

Moderna NASDAQ:MRNA

$25.11 -0.62 (-2.41%)
Closing price 04/4/2025 04:00 PM Eastern
Extended Trading
$24.92 -0.19 (-0.75%)
As of 04/4/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Roivant Sciences stock logo

Roivant Sciences NASDAQ:ROIV

$9.46 -0.55 (-5.49%)
Closing price 04/4/2025 04:00 PM Eastern
Extended Trading
$9.46 -0.01 (-0.05%)
As of 04/4/2025 06:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Teva Pharmaceutical Industries stock logo

Teva Pharmaceutical Industries NYSE:TEVA

$13.83 -1.02 (-6.87%)
Closing price 04/4/2025 03:59 PM Eastern
Extended Trading
$13.78 -0.04 (-0.33%)
As of 04/4/2025 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.